PL1801209T3 - Zmodyfikowany genomowy RNA ludzkiego wirusa zapalenia wątroby typu C posiadający zdolność replikacji autonomicznej - Google Patents
Zmodyfikowany genomowy RNA ludzkiego wirusa zapalenia wątroby typu C posiadający zdolność replikacji autonomicznejInfo
- Publication number
- PL1801209T3 PL1801209T3 PL05781421T PL05781421T PL1801209T3 PL 1801209 T3 PL1801209 T3 PL 1801209T3 PL 05781421 T PL05781421 T PL 05781421T PL 05781421 T PL05781421 T PL 05781421T PL 1801209 T3 PL1801209 T3 PL 1801209T3
- Authority
- PL
- Poland
- Prior art keywords
- coding sequence
- protein coding
- genomic rna
- virus genomic
- hepatitis
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title abstract 4
- 230000003362 replicative effect Effects 0.000 title 1
- 108091026890 Coding region Proteins 0.000 abstract 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 4
- 101710144111 Non-structural protein 3 Proteins 0.000 abstract 3
- 101800001014 Non-structural protein 5A Proteins 0.000 abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 3
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 abstract 3
- 101710159910 Movement protein Proteins 0.000 abstract 2
- 101710144117 Non-structural protein 4 Proteins 0.000 abstract 2
- 101710132601 Capsid protein Proteins 0.000 abstract 1
- 241000711557 Hepacivirus Species 0.000 abstract 1
- 101710125507 Integrase/recombinase Proteins 0.000 abstract 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 abstract 1
- 101710144128 Non-structural protein 2 Proteins 0.000 abstract 1
- 101800001020 Non-structural protein 4A Proteins 0.000 abstract 1
- 101800001019 Non-structural protein 4B Proteins 0.000 abstract 1
- 101710199667 Nuclear export protein Proteins 0.000 abstract 1
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 abstract 1
- 108091036066 Three prime untranslated region Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24241—Use of virus, viral particle or viral elements as a vector
- C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Pathology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004243975 | 2004-08-24 | ||
| JP2004290801 | 2004-10-01 | ||
| JP2005069725 | 2005-03-11 | ||
| JP2005069527 | 2005-03-11 | ||
| EP05781421A EP1801209B1 (en) | 2004-08-24 | 2005-08-24 | Modified human hepatitis c virus genomic rna having autonomous replicative competence |
| PCT/JP2005/015833 WO2006022422A1 (ja) | 2004-08-24 | 2005-08-24 | 自律複製能を有する改変されたヒトｃ型肝炎ウイルスゲノムrna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1801209T3 true PL1801209T3 (pl) | 2011-07-29 |
Family
ID=35967617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05781421T PL1801209T3 (pl) | 2004-08-24 | 2005-08-24 | Zmodyfikowany genomowy RNA ludzkiego wirusa zapalenia wątroby typu C posiadający zdolność replikacji autonomicznej |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8454973B2 (pl) |
| EP (1) | EP1801209B1 (pl) |
| JP (1) | JP4931591B2 (pl) |
| KR (1) | KR101262773B1 (pl) |
| CN (1) | CN101048502B (pl) |
| AT (1) | ATE499442T1 (pl) |
| AU (1) | AU2005275713B2 (pl) |
| CA (1) | CA2578021C (pl) |
| DE (1) | DE602005026545D1 (pl) |
| PL (1) | PL1801209T3 (pl) |
| PT (1) | PT1801209E (pl) |
| WO (1) | WO2006022422A1 (pl) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5086082B2 (ja) * | 2004-10-01 | 2012-11-28 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | Ｃ型肝炎ウイルス複製系 |
| AU2006220887B2 (en) | 2005-03-04 | 2010-11-04 | The Rockefeller University | Infectious, chimeric Hepatitis C Virus, methods of producing the same and methods of use thereof |
| US8364417B2 (en) * | 2007-02-15 | 2013-01-29 | 454 Life Sciences Corporation | System and method to correct out of phase errors in DNA sequencing data by use of a recursive algorithm |
| US8301394B2 (en) * | 2006-02-16 | 2012-10-30 | 454 Life Sciences Corporation | System and method for correcting primer extension errors in nucleic acid sequence data |
| JP2008161080A (ja) * | 2006-12-27 | 2008-07-17 | Japan Health Science Foundation | Ｃ型肝炎ウイルス阻害剤を検出するためのアッセイ方法 |
| US8945584B2 (en) | 2007-04-13 | 2015-02-03 | Hvidovre Hospital | Cell culture system of a hepatitis C genotype 3a and 2a chimera |
| US8454974B2 (en) | 2007-04-13 | 2013-06-04 | Hvidovre Hospital | Adaptive mutations allow establishment of JFH1-based cell culture systems for hepatitis C virus genotype 4A |
| EP2151495A4 (en) * | 2007-04-27 | 2010-06-02 | Advanced Life Science Inst Inc | HCV GENE |
| US8618275B2 (en) | 2007-05-18 | 2013-12-31 | Hvidovre Hospital | Efficient cell culture system for hepatitis C virus genotype 5A |
| CA2696437A1 (en) * | 2007-07-13 | 2009-01-22 | Toray Industries, Inc. | Production and use of epitope-tagged hepatitis c virus particle |
| CN101809033A (zh) | 2007-07-25 | 2010-08-18 | 日本国立感染症研究所 | 对丙型肝炎病毒(hcv)感染具有抑制活性的抗体和其用途 |
| EP2235164A1 (en) * | 2007-12-20 | 2010-10-06 | Hvidovre Hospital | Efficient cell culture system for hepatitis c virus genotype 1a and 1b |
| US8569472B2 (en) | 2007-12-20 | 2013-10-29 | Hvidovre Hospital | Efficient cell culture system for hepatitis C virus genotype 6A |
| WO2009131203A1 (ja) | 2008-04-25 | 2009-10-29 | 東レ株式会社 | C型肝炎ウイルス由来のキメラ遺伝子を含む核酸 |
| WO2010017819A1 (en) | 2008-08-15 | 2010-02-18 | Hvidovre Hospital | EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 7a |
| US8663653B2 (en) | 2008-08-15 | 2014-03-04 | Hvidovre Hospital | Efficient cell culture system for hepatitis C virus genotype 2B |
| EP2336173A4 (en) | 2008-09-30 | 2012-07-25 | Toray Industries | FOR BINDING THE CROP PROTEIN 2 OF THE HEPATITIS C-VIRUS CAPACITIVE ANTIBODY AND METHOD FOR IDENTIFYING THE GENOTYPIC OF THE HEPATITIS C VIRUS USING THEREOF |
| EP2344647A1 (en) | 2008-10-03 | 2011-07-20 | Hvidovre Hospital | Hepatitis c virus expressing reporter tagged ns5a protein |
| JP5692738B2 (ja) * | 2009-07-28 | 2015-04-01 | 国立大学法人 鹿児島大学 | ウイルスの濃縮方法および磁性体組成物 |
| EP2484378A4 (en) | 2009-09-30 | 2013-05-22 | Toray Industries | HEPATITIS C VIRUS VACCINE COMPOSITION |
| CN102596996B (zh) | 2009-10-30 | 2014-06-18 | 东丽株式会社 | 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途 |
| EP2580353B1 (en) | 2010-06-11 | 2015-07-29 | Life Technologies Corporation | Alternative nucleotide flows in sequencing-by-synthesis methods |
| US8981073B2 (en) * | 2010-10-08 | 2015-03-17 | Advanced Life Science Institute, Inc. | Hepatitis C virus gene |
| US10273540B2 (en) | 2010-10-27 | 2019-04-30 | Life Technologies Corporation | Methods and apparatuses for estimating parameters in a predictive model for use in sequencing-by-synthesis |
| EP2633470B1 (en) | 2010-10-27 | 2016-10-26 | Life Technologies Corporation | Predictive model for use in sequencing-by-synthesis |
| US9594870B2 (en) | 2010-12-29 | 2017-03-14 | Life Technologies Corporation | Time-warped background signal for sequencing-by-synthesis operations |
| US10146906B2 (en) | 2010-12-30 | 2018-12-04 | Life Technologies Corporation | Models for analyzing data from sequencing-by-synthesis operations |
| WO2012092515A2 (en) | 2010-12-30 | 2012-07-05 | Life Technologies Corporation | Methods, systems, and computer readable media for nucleic acid sequencing |
| US20130060482A1 (en) | 2010-12-30 | 2013-03-07 | Life Technologies Corporation | Methods, systems, and computer readable media for making base calls in nucleic acid sequencing |
| US9234184B2 (en) | 2011-03-31 | 2016-01-12 | Japan As Represented By Director-General Of National Institute Of Infectious Diseases | Nucleic acid construct comprising nucleic acid derived from genome of hepatitis C virus of genotype 1B, hepatitis C virus genome-replicating cells transfected with the same, and method for producing infectious hepatitis C virus particles |
| CN105861645B (zh) | 2011-04-08 | 2020-02-21 | 生命科技股份有限公司 | 用于合成测序中的相保护试剂流排序 |
| WO2012165542A1 (ja) | 2011-05-31 | 2012-12-06 | 国立感染症研究所長が代表する日本国 | Ｃ型肝炎ウイルスｊ６ｃｆ株ゲノム由来の変異体レプリコン |
| WO2013031956A1 (ja) | 2011-08-31 | 2013-03-07 | 国立感染症研究所長が代表する日本国 | 遺伝子型３aのＣ型肝炎ウイルスゲノム由来の核酸を含む核酸構築物 |
| US20150087537A1 (en) | 2011-08-31 | 2015-03-26 | Life Technologies Corporation | Methods, Systems, Computer Readable Media, and Kits for Sample Identification |
| US10704164B2 (en) | 2011-08-31 | 2020-07-07 | Life Technologies Corporation | Methods, systems, computer readable media, and kits for sample identification |
| EP2802597A1 (en) * | 2012-01-13 | 2014-11-19 | Gilead Pharmasset LLC | Crysral structure of hcv polymerase complexes and methods of use |
| US9646132B2 (en) | 2012-05-11 | 2017-05-09 | Life Technologies Corporation | Models for analyzing data from sequencing-by-synthesis operations |
| US10329608B2 (en) | 2012-10-10 | 2019-06-25 | Life Technologies Corporation | Methods, systems, and computer readable media for repeat sequencing |
| US20140296080A1 (en) | 2013-03-14 | 2014-10-02 | Life Technologies Corporation | Methods, Systems, and Computer Readable Media for Evaluating Variant Likelihood |
| US9926597B2 (en) | 2013-07-26 | 2018-03-27 | Life Technologies Corporation | Control nucleic acid sequences for use in sequencing-by-synthesis and methods for designing the same |
| WO2015051338A1 (en) | 2013-10-04 | 2015-04-09 | Life Technologies Corporation | Methods and systems for modeling phasing effects in sequencing using termination chemistry |
| US10676787B2 (en) | 2014-10-13 | 2020-06-09 | Life Technologies Corporation | Methods, systems, and computer-readable media for accelerated base calling |
| CN114540475B (zh) | 2015-05-14 | 2025-07-29 | 生命科技公司 | 条形码序列和有关系统与方法 |
| US10619205B2 (en) | 2016-05-06 | 2020-04-14 | Life Technologies Corporation | Combinatorial barcode sequences, and related systems and methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4021493B2 (ja) * | 1996-11-08 | 2007-12-12 | ザ ガヴァメント オブ ザ ユナイテッド ステイツ オブ アメリカ、レプリゼンテッド バイ ザ セクレタリー、 デパートメント オブ ヘルス アンド ヒューマン サーヴィスィズ | Ｃ型肝炎ウイルス様粒子の合成および精製 |
| AU5322800A (en) * | 1999-06-04 | 2000-12-28 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Cloned genone of infectious hepatitis c virus of genotype 2a and uses thereof |
| DE60040755D1 (de) * | 1999-12-01 | 2008-12-18 | Novartis Vaccines & Diagnostic | Hervorrufen von antikörpern spezifisch für hepatitis c virus (hcv) |
| IL137522A (en) * | 2000-07-26 | 2007-06-17 | Drk Blutspendediendst Baden Wu | HCV human monoclonal antibody E2 glycoprotein antibody |
| JP4880116B2 (ja) * | 2000-12-01 | 2012-02-22 | 財団法人 東京都医学総合研究所 | 劇症ｃ型肝炎ウイルス株の遺伝子 |
| EP1490389A4 (en) | 2002-04-03 | 2006-08-09 | Smithkline Beecham Corp | SUBGENOMIC REPLICONS OF HEPATITIS C VIRUS |
| CN1833024B (zh) * | 2003-05-26 | 2011-08-31 | 东丽株式会社 | 含有衍生自基因型2a丙肝病毒(HCV)基因组的核酸的核酸构建体和具有转移入其中的这样的核酸构建体的细胞 |
| JP5086082B2 (ja) * | 2004-10-01 | 2012-11-28 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | Ｃ型肝炎ウイルス複製系 |
| AU2006220887B2 (en) * | 2005-03-04 | 2010-11-04 | The Rockefeller University | Infectious, chimeric Hepatitis C Virus, methods of producing the same and methods of use thereof |
| WO2009131203A1 (ja) * | 2008-04-25 | 2009-10-29 | 東レ株式会社 | C型肝炎ウイルス由来のキメラ遺伝子を含む核酸 |
-
2005
- 2005-08-24 PT PT05781421T patent/PT1801209E/pt unknown
- 2005-08-24 EP EP05781421A patent/EP1801209B1/en not_active Expired - Lifetime
- 2005-08-24 CA CA2578021A patent/CA2578021C/en not_active Expired - Lifetime
- 2005-08-24 JP JP2006532743A patent/JP4931591B2/ja not_active Expired - Lifetime
- 2005-08-24 US US11/660,794 patent/US8454973B2/en active Active
- 2005-08-24 AU AU2005275713A patent/AU2005275713B2/en not_active Expired
- 2005-08-24 CN CN2005800364134A patent/CN101048502B/zh not_active Expired - Lifetime
- 2005-08-24 WO PCT/JP2005/015833 patent/WO2006022422A1/ja not_active Ceased
- 2005-08-24 AT AT05781421T patent/ATE499442T1/de not_active IP Right Cessation
- 2005-08-24 KR KR1020077006497A patent/KR101262773B1/ko not_active Expired - Lifetime
- 2005-08-24 PL PL05781421T patent/PL1801209T3/pl unknown
- 2005-08-24 DE DE602005026545T patent/DE602005026545D1/de not_active Expired - Lifetime
-
2013
- 2013-01-04 US US13/734,630 patent/US9175269B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP1801209A4 (en) | 2007-12-05 |
| KR101262773B1 (ko) | 2013-05-10 |
| EP1801209B1 (en) | 2011-02-23 |
| CN101048502A (zh) | 2007-10-03 |
| PT1801209E (pt) | 2011-05-26 |
| DE602005026545D1 (de) | 2011-04-07 |
| WO2006022422A1 (ja) | 2006-03-02 |
| US20130115592A1 (en) | 2013-05-09 |
| EP1801209A1 (en) | 2007-06-27 |
| US8454973B2 (en) | 2013-06-04 |
| HK1112481A1 (en) | 2008-09-05 |
| AU2005275713A1 (en) | 2006-03-02 |
| ATE499442T1 (de) | 2011-03-15 |
| JPWO2006022422A1 (ja) | 2008-05-08 |
| US9175269B2 (en) | 2015-11-03 |
| US20090176200A1 (en) | 2009-07-09 |
| CN101048502B (zh) | 2012-03-21 |
| CA2578021C (en) | 2014-11-18 |
| AU2005275713B2 (en) | 2010-08-05 |
| JP4931591B2 (ja) | 2012-05-16 |
| CA2578021A1 (en) | 2006-03-02 |
| KR20070045333A (ko) | 2007-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1801209T3 (pl) | Zmodyfikowany genomowy RNA ludzkiego wirusa zapalenia wątroby typu C posiadający zdolność replikacji autonomicznej | |
| WO2009014216A1 (ja) | Ｃ型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体およびその用途 | |
| Epstein et al. | Identification of GBV-D, a novel GB-like flavivirus from old world frugivorous bats (Pteropus giganteus) in Bangladesh | |
| Fan et al. | The intrinsic disorder status of the human hepatitis C virus proteome | |
| Ezelle et al. | Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector | |
| WO2006096459A3 (en) | Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof | |
| JP2008516610A5 (pl) | ||
| DK1629091T3 (da) | Præparat indeholdende polyproteinet NS3/NS4 og polypeptidet NS5B af HCV, ekspressionsvektorer omfattende tilsvarende nukleinsyresekvenser og terapeutisk anvendelse deraf | |
| Naderi et al. | Hepatitis C virus and vaccine development | |
| Londono-Renteria et al. | A brief review of West Nile virus biology | |
| Khasnatinov et al. | Tick-borne encephalitis virus structural proteins are the primary viral determinants of non-viraemic transmission between ticks whereas non-structural proteins affect cytotoxicity | |
| ATE555800T1 (de) | Zusammensetzung mit dem polyprotein ns3/ns4 und dem polypeptid ns5b von hcv, expressionsvektoren mit den entsprechenden nukleinsäuresequenzen und ihre therapeutische verwendung | |
| Manickam et al. | Modeling HCV disease in animals: virology, immunology and pathogenesis of HCV and GBV-B infections | |
| Varshney et al. | A review on an update of NS5B polymerase hepatitis C virus inhibitors | |
| McElroy et al. | Characterization of an infectious clone of the wild-type yellow fever virus Asibi strain that is able to infect and disseminate in mosquitoes | |
| EP1930416A4 (en) | NEW RECOMBINANT PARTICLE SIMILAR TO HUMAN HEPATITIS C VIRUS AND METHOD FOR THE MANUFACTURE THEREOF | |
| WO2008136470A1 (ja) | Ｈｃｖ遺伝子 | |
| WO2005032329A3 (en) | Methods and compositions for identifying anti-hcv agents | |
| Suzuki et al. | Positively selected amino acid sites in the entire coding region of hepatitis C virus subtype 1b | |
| Lattwein et al. | Pestivirus virion morphogenesis in the absence of uncleaved nonstructural protein 2-3 | |
| Pham et al. | Efficient hepatitis C virus genotype 1b core-NS5A recombinants permit efficacy testing of protease and NS5A inhibitors | |
| Bittar et al. | Genetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy response | |
| WO2016066171A1 (en) | Optimized hcv full-length infectious cell culture systems and applications thereof | |
| CN104126008A (zh) | 包含来自基因型3a的丙型肝炎病毒基因组的核酸的核酸构建物 | |
| Sarwar et al. | NS4A protein as a marker of HCV history suggests that different HCV genotypes originally evolved from genotype 1b |